FGF2 Mouse anti-Human, Clone: 10060, Invitrogen
Mouse Monoclonal Antibody
Manufacturer: Invitrogen MA523703
In capture ELISAs, this antibody shows approximately 0.2% cross-reactivity with bovine FGF acidic, and no cross-reactivity with rhFGF acidic, rhFGF-4, rhFGF-6, or rhFGF-7. Reconstitute at 0.5 mg/mL in sterile PBS.FGF2 (FGFb, fibroblast growth factor basic) belongs to the fibroblast growth factor (FGF) family, and interacts with high-affinity transmembrane receptors to influence cell proliferation and tissue neovascularization. FGF2 exists as five isoforms with distinct intracellular localizations and functions. The 18 kDa isoform is predomitly cytosolic and acts through cell surface receptors, whereas the 22, 22.5, 24 and 34 kDa isoforms are nuclear and may signal independent of transmembrane receptor pathways. In humans, the gene is located on the q arm of chromosome 4. FGF2 has been implicated in diverse biological processes, such as limb and nervous system development, wound healing, and tumor growth. The mRNA for FGF2 contains multiple polyadenylation sites, and is alternatively translated from non-AUG and AUG initiation codons, resulting in five different isoforms with distinct properties. The CUG-initiated isoforms are localized in the nucleus and are responsible for the intracrine effect, whereas, the AUG-initiated form is mostly cytosolic and is responsible for the paracrine and autocrine effects of this FGF. Diseases associated with FGF2 dysfunction include Kaposi Sarcoma and corneal neovascularization.
|PBS with 5% trehalose and No Preservative|
|BFGF, FGFB, HBGF-2, basic fibroblast growth factor bFGF, heparin-binding growth factor 2, prostatropin|
|-20° C, Avoid Freeze/Thaw Cycles|
|E. coli-derived recombit human FGF basic|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok